World Sleep Industry ENCYCLOPEDIA

silktree albizia bark (He huan pi) extract

3.1.3

Definition, botanical source, and category boundary

Silktree albizia bark extract is a botanical preparation made from the dried stem bark of the legume Albizia julibrissin Durazz. by extraction with water, aqueous ethanol, or another declared process, followed by concentration and drying as applicable. It is placed in WSIC 3.1.3 so that it can be retrieved and compared within the industry grouping for traditional medicine–related foods and supplements. That classification is not an authorization for ordinary food use, a medicine approval, or a conclusion that the extract improves sleep.

Albizia bark and albizia flower are different plant parts even though they come from the same species; their monographs, composition, and evidence cannot be interchanged. A bark decoction piece, directly powdered bark, extracts made with different solvents, a purified saponin fraction, and a multi-ingredient formula containing bark are also different study objects. A label that states only “albizia,” “silktree,” or “botanical extract” does not establish identity. The full scientific name, plant part, preparation type, and actual amount in the finished product are needed, together with controls against substitution by another Albizia species or similarly named material.

Extraction, composition, and dose comparability

Solvent, solvent strength, temperature, duration, particle size, concentration, and purification can change which constituents are recovered and in what proportions. Research on the genus discusses triterpenoid saponins, flavonoids, lignanoids, and phenolic glycosides, among other groups. Detecting one class does not identify a proven sleep-active constituent, and one marker cannot by itself represent total quality. Terms such as high-ratio, full-spectrum, or standardized are meaningful only when the specification, analytical method, and acceptance range are disclosed.

A comparable declaration identifies the drug-to-extract ratio and its range, extraction solvent and strength, proportion of genuine extract, carriers or anticaking agents, amount of extract per serving, and equivalent starting material. The same “500 mg” may represent different quantities of bark, water, and excipients. Different extracts cannot be substituted solely by matching their herb-equivalent figures. A dose per kilogram used in an animal experiment, a traditional amount of decoction pieces, and a finished-extract serving belong to different systems and should not be converted into a self-directed human regimen.

Identity, quality, and batch control

Incoming material should be traceable to species, stem-bark part, origin, harvest, and processing. Pharmacopoeial or other applicable macroscopic, microscopic, and chemical methods should exclude the wrong species, wrong part, and adulteration. Extraction removes many visible identification features, making a process-appropriate chromatographic fingerprint, identification peaks or marker ranges, and a batch chain from bark through concentrate to finished product especially important. A flower report, a paper about another Albizia species, or a generic botanical certificate does not establish the identity of this bark extract.

Finished specifications should also address water or loss on drying, microorganisms, pesticide residues, metals and metalloids, mycotoxins, residual solvents, solvent-recovery risks, undeclared substances, packaging compatibility, and stability through shelf life, using limits and methods applicable in the target market. Institutional purchasing should review supplier changes, deviations, retained samples, method suitability, and recall capacity. A “third-party tested” statement is interpretable only when it identifies the lot, analytes, methods, and acceptance criteria.

Sleep evidence and interpretation of results

Albizia bark has traditional uses related to emotional distress and sleep, but a traditional record supplies historical context rather than evidence that a modern finished extract has passed a randomized human trial. Current research is dominated by animal behavioral experiments on bark extracts, in-vitro or animal mechanism studies of isolated constituents, and animal studies of multi-herb formulas containing the bark. Anxiety-like behavior in a maze, pentobarbital-induced sleep, or neurotransmitter changes in animals do not directly demonstrate improvement of human insomnia or establish long-term safety.

Published reviews note that the Albizia genus has extensive traditional and preclinical literature but lacks clinical evidence supporting health benefits. Research on the flower cannot stand in for bark, and an effect of a formula cannot be assigned to one ingredient. A claim about sleep onset, nighttime awakening, or sleep quality requires a human study of the specific extract and final formulation, with the population, comparator, randomization and masking, duration, insomnia definition, objective or subjective outcomes, adverse events, and withdrawals reported. A mechanism, testimonial, or statistically significant surrogate alone does not establish meaningful clinical benefit.

Use, population safety, and risk communication

There is no self-care dose that can be applied across albizia bark extracts. Before use, the legal product category, actual amount per serving, and instructions in the jurisdiction should be confirmed. A decoction-piece amount, animal dose, or serving of a different extract ratio should not be copied. Persistent insomnia, marked low mood, breathing interruptions, abnormal sleepiness, or an immediate safety concern requires professional assessment; a supplement must not delay diagnosis or replace established care.

When adequate human data are absent for long-term use, pregnancy, breastfeeding, children, or people with impaired liver or kidney function, unsupervised use is inappropriate. A person taking medicines, drinking alcohol, combining other products that affect alertness, or preparing for surgery should show the complete product and dose to a physician or pharmacist rather than assuming that interactions do not exist. Natural origin does not mean freedom from adverse effects. Rash, swelling of the face or lips, breathing difficulty, persistent gastrointestinal symptoms, pronounced dizziness, palpitations, unusual drowsiness, jaundice, or dark urine calls for discontinuation and timely medical assessment and reporting according to severity.

Trial records, storage, and service life

If a qualified professional considers use reasonable, evaluation should keep one ingredient and one stable plan rather than adding several botanicals, sedating products, or alcohol at the same time. Record the lot, actual daily intake, timing, sleep schedule, caffeine and alcohol exposure, sleep onset and awakenings, next-day alertness, and any symptoms. Stop and reassess when benefit is not repeatable, daytime function deteriorates, or an adverse effect appears; increasing the amount or stacking products does not resolve an uncertain signal.

Powders and capsules should be kept closed, dry, and protected from light as the label directs. Liquid products also need a defined temperature and in-use period after opening. Caking, moisture uptake, separation, unusual color or odor, a damaged seal, an unreadable lot, or expiry are reasons not to continue use. Keep the original package, instructions, and purchase record for a reasonable period after use so that the lot can be identified during a complaint or recall. Long-term storage in an unlabelled repacked container removes identity, storage, and traceability information.

Compliance, labeling, and procurement judgment

Recognition of albizia bark as a traditional medicinal material does not automatically give its extract ordinary-food status. Depending on the jurisdiction, the material or finished preparation may be regulated as a Chinese medicinal material, decoction piece, proprietary medicine, herbal medicine, health food, dietary supplement, novel food, or an ingredient not permitted in ordinary foods. Plant part, extraction process, degree of concentration, dose, and claims can change the classification. Manufacturers, importers, and sellers must check the current lists, authorizations, quality standards, and labeling rules in the destination market; a WSIC placement or evidence of sale elsewhere is not a regulatory determination.

Labels and procurement records should state the complete botanical name, stem-bark part, extraction solvent, drug-to-extract ratio, genuine extract and excipients, amount per serving, recommended and maximum use, warnings, lot, expiry, and responsible business. Statements such as “pharmacopoeial source,” “clinically validated,” “patented extraction,” “free of side effects,” or “treats insomnia” must match the exact object and scope of supporting evidence. Correct identity of the starting bark does not prove finished-product efficacy, and a factory quality-system audit does not authorize a health claim.